BofA analyst David Li raised the firm’s price target on BeOne Medicines (ONC) to $350 from $340 and keeps a Buy rating on the shares after “robust” sales growth in Q2, driven by strong Brukinsa sales in the U.S. and EU. Following the results and guidance, the firm raised its 2025, 2026 and 2027 revenue estimates by 1.3%, 1.7% and 2.3%, respectively.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeOne Medicines price target raised to $360 from $334 at TD Cowen
- BeOne Medicines: Strong Financial Performance and Strategic Positioning Justify Buy Rating
- BeOne Medicines Reports Strong Q2 2025 Performance
- BeiGene’s Earnings Call Highlights Robust Growth and Market Leadership
- BeOne Medicines: Strong Financial Performance and Promising Pipeline Justify Buy Rating and Increased Price Target